Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Manuela Onidi"'
Autor:
Sven Jaeckel, Annika Hansen, Nina Glaser, Sigrid Johannes, Willem Sloot, Valentina Lai, Juergen Hellmann, Anja Knippel, Manuela Onidi
Publikováno v:
Toxicology and applied pharmacology. 429
M3258 is the first selective inhibitor of the immunoproteasome subunit LMP7 (Large multifunctional protease 7) in early clinical development with the potential to improve therapeutic utility in patients of multiple myeloma (MM) or other hematological
Autor:
Enrico Vigna, Manuela Onidi, Juergen Hellmann, Anja Knippel, Andrea Paoletti, Ping Yu, Christina Esdar
Publikováno v:
Toxicology and applied pharmacology. 406
Blocking Fibroblast Growth Factor Receptor 1 (FGFR1) is an attractive therapeutic option for treatment of cancer subtypes with amplification and over-expression of FGFR1. Selective targeting of FGFR1 can be achieved using an antibody-based approach,
Autor:
Derek Janszen, Enrico Vigna, Sergio Peano, Manuela Onidi, Mauro Bertolino, Rafael A. Ponce, Chiara Daghero, Laura Fava, Ping Yu, Jennifer Visich, Michela Carbonatto, Stephanie Steidler, Bruno Roattino, Stacey R. Dillon, Michele Ardizzone
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 105(1)
Atacicept, a soluble recombinant fusion protein of the human immunoglobulin (Ig) G1 Fc and the extracellular domain of the human transmembrane activator and calcium modulator and cyclophylin ligand interactor receptor, acts as an antagonist of both B
Publikováno v:
Toxicology Letters. 211:S157-S158
Autor:
Michela Carbonatto, Ping Yu, Mauro Bertolino, Enrico Vigna, Stephanie Steidler, Laura Fava, Chiara Daghero, Bruno Roattino, Manuela Onidi, Michele Ardizzone, Sergio Peano, Jennifer Visich, Derek Janszen, Stacey Dillon, Rafael Ponce
Publikováno v:
Toxicological Sciences; Sep2008, Vol. 105 Issue 1, p200-200, 1p